kabutan

Immuno-Biological Lab, 15% Increase in Ordinary Profit, Update Record High for Second Consecutive Term, Resuming Dividends at 6 yen for the First Time in Thirteen Terms

Wed May 14, 2025 3:30 pm JST Earnings

4570 Immuno-Biological Laboratories Co., Ltd. 【J-GAAP】

Earnings Report

Immuno-Biological Laboratories Co., Ltd. <4570> [TSE Growth] announced its financial results after the market closed on May 14th (15:30). The consolidated ordinary profit for the fiscal year ending March 2025 expanded 67.2% from the previous period to 209 million yen, exceeding the previous forecast of 180 million yen. For the fiscal year ending March 2026, the consolidated ordinary profit is expected to grow by 14.8% to 240 million yen, marking the second consecutive term of record-high profits. This will be the sixth consecutive term of revenue growth.

At the same time, the company plans to pay a final dividend of 6 yen, reinstating dividends for the first time in thirteen terms.

In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit decreased to 80 million yen, a 20.0% decrease compared to the same period last year. The operating profit margin decreased from 35.1% in the same period last year to 29.4%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 794 57 -149 -289 -31.1 0 May 12, 2023 J-GAAP
Mar, 2024 816 104 125 186 20.1 0 May 14, 2024 J-GAAP
Mar, 2025 969 209 209 249 26.7 0 May 14, 2025 J-GAAP
YoY +18.8% +101.0% +67.2% +33.9% +33.4%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 925 180 180 215 23.1 0 Feb 18, 2025 J-GAAP
Mar, 2025 Results 969 209 209 249 26.7 0 May 14, 2025 J-GAAP
Revision Rate +4.8% +16.1% +16.1% +15.8% +15.9%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 444 68 64 71 7.7 0 Nov 11, 2024 J-GAAP
Apr - Sep, 2025 Guidance ー ー ー ー － 0 May 14, 2025 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 816 104 125 186 20.1 0 May 14, 2024 J-GAAP
Mar, 2025 969 209 209 249 26.7 0 May 14, 2025 J-GAAP
Mar, 2026 Guidance 1,025 240 240 265 28.5 6 May 14, 2025 J-GAAP
YoY +5.8% +14.8% +14.8% +6.4% +6.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 268 94 100 166 17.9 35.1 May 14, 2024 J-GAAP
Apr - Jun, 2024 229 51 56 51 5.5 22.3 Aug 8, 2024 J-GAAP
Jul - Sep, 2024 215 17 8 20 2.2 7.9 Nov 11, 2024 J-GAAP
Oct - Dec, 2024 236 56 65 62 6.7 23.7 Feb 10, 2025 J-GAAP
Jan - Mar, 2025 289 85 80 116 12.5 29.4 May 14, 2025 J-GAAP
YoY +7.8% -9.6% -20.0% -30.1% -30.4%

Related Articles